Spatially-targeted tuberculosis screening has limited impact beyond household contact tracing in Lima, Peru: A model-based analysis.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2023
Historique:
received: 21 10 2022
accepted: 15 10 2023
medline: 1 11 2023
pubmed: 30 10 2023
entrez: 30 10 2023
Statut: epublish

Résumé

Mathematical models have suggested that spatially-targeted screening interventions for tuberculosis may efficiently accelerate disease control, but empirical data supporting these findings are limited. Previous models demonstrating substantial impacts of these interventions have typically simulated large-scale screening efforts and have not attempted to capture the spatial distribution of tuberculosis in households and communities at a high resolution. Here, we calibrate an individual-based model to the locations of case notifications in one district of Lima, Peru. We estimate the incremental efficiency and impact of a spatially-targeted interventions used in combination with household contact tracing (HHCT). Our analysis reveals that HHCT is relatively efficient with a median of 40 (Interquartile Range: 31.7 to 49.9) household contacts required to be screened to detect a single case of active tuberculosis. However, HHCT has limited population impact, producing a median incidence reduction of only 3.7% (Interquartile Range: 5.8% to 1.9%) over 5 years. In comparison, spatially targeted screening (which we modeled as active case finding within high tuberculosis prevalence areas 100 m2 grid cell) is far less efficient, requiring evaluation of ≈12 times the number of individuals as HHCT to find a single individual with active tuberculosis. Furthermore, the addition of the spatially targeted screening effort produced only modest additional reductions in tuberculosis incidence over the 5 year period (≈1.3%) in tuberculosis incidence. In summary, we found that HHCT is an efficient approach for tuberculosis case finding, but has limited population impact. Other screening approaches which target areas of high tuberculosis prevalence are less efficient, and may have limited impact unless very large numbers of individuals can be screened.

Identifiants

pubmed: 37903091
doi: 10.1371/journal.pone.0293519
pii: PONE-D-22-29130
pmc: PMC10615320
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0293519

Subventions

Organisme : NIAID NIH HHS
ID : R01 AI147854
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI124386
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI146555
Pays : United States
Organisme : NIAID NIH HHS
ID : U19 AI076217
Pays : United States

Informations de copyright

Copyright: © 2023 Havumaki et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

BMC Infect Dis. 2017 Oct 2;17(1):662
pubmed: 28969585
Lancet. 2015 May 2;385(9979):1799-1801
pubmed: 25814376
Am J Respir Crit Care Med. 2006 Sep 1;174(5):599-604
pubmed: 16728707
BMC Infect Dis. 2018 Jul 4;18(1):299
pubmed: 29973140
Biometrika. 1950 Jun;37(1-2):17-23
pubmed: 15420245
PLoS Comput Biol. 2021 Feb 8;17(2):e1008713
pubmed: 33556077
Int J Epidemiol. 2018 Feb 1;47(1):185-192
pubmed: 29025111
Lancet. 2010 Oct 9;376(9748):1205-6
pubmed: 20923714
PLoS One. 2011 Apr 04;6(4):e17601
pubmed: 21483732
Proc Natl Acad Sci U S A. 2022 Nov 08;119(45):e2207022119
pubmed: 36322726
Trends Parasitol. 2019 Oct;35(10):822-834
pubmed: 31474558
BMC Med. 2018 Aug 3;16(1):122
pubmed: 30071850
Nature. 2006 Jan 26;439(7075):462-5
pubmed: 16437114
Lancet Infect Dis. 2018 Aug;18(8):e228-e238
pubmed: 29653698
Int J Tuberc Lung Dis. 2010 Feb;14(2):203-9
pubmed: 20074412
Lancet Infect Dis. 2019 Mar;19(3):e89-e95
pubmed: 30554997
Emerg Infect Dis. 2007 Oct;13(10):1491-3
pubmed: 18257992
PLoS Med. 2010 Dec 21;7(12):e1000381
pubmed: 21203587
Bull World Health Organ. 2003;81(11):799-805
pubmed: 14758406
Proc Natl Acad Sci U S A. 2012 Jun 12;109(24):9557-62
pubmed: 22645356
Lancet. 2013 Oct 5;382(9899):1183-94
pubmed: 23915882
Am J Respir Crit Care Med. 2014 Apr 1;189(7):845-52
pubmed: 24559425
Lancet Glob Health. 2018 Apr;6(4):e426-e435
pubmed: 29472018
Clin Infect Dis. 2012 Mar;54(6):784-91
pubmed: 22267721
Am J Respir Crit Care Med. 2014 Nov 15;190(10):1168-76
pubmed: 25303140
N Engl J Med. 2019 Oct 3;381(14):1347-1357
pubmed: 31577876
Int J Health Geogr. 2020 Sep 9;19(1):34
pubmed: 32907588
PLoS One. 2020 May 22;15(5):e0233358
pubmed: 32442201
Emerg Infect Dis. 2006 Dec;12(12):1822-6
pubmed: 17326931
Int J Tuberc Lung Dis. 2006 Apr;10(4):415-21
pubmed: 16602406
PLoS One. 2012;7(10):e46029
pubmed: 23056227
R Soc Open Sci. 2018 Sep 19;5(9):180887
pubmed: 30839742
PLoS One. 2013 Jun 27;8(6):e67516
pubmed: 23826313
PLoS Med. 2019 Jan 24;16(1):e1002737
pubmed: 30677013
Emerg Infect Dis. 2015 Mar;21(3):452-5
pubmed: 25642998
Lancet Glob Health. 2020 Sep;8(9):e1223-e1233
pubmed: 32827484
Am J Infect Control. 2013 Feb;41(2):155-60
pubmed: 22750037
Am J Respir Crit Care Med. 2012 May 15;185(10):1110-6
pubmed: 22427532
PLoS One. 2012;7(4):e34411
pubmed: 22496801
Cochrane Database Syst Rev. 2004;(1):CD000171
pubmed: 14973947
Am J Epidemiol. 2014 Oct 15;180(8):853-61
pubmed: 25190676
Eur Respir J. 2020 Mar 5;55(3):
pubmed: 31949119
Lancet. 2010 Oct 9;376(9748):1244-53
pubmed: 20923715
J Infect Dis. 2011 Jun 1;203(11):1582-9
pubmed: 21592987

Auteurs

Joshua Havumaki (J)

Department of Epidemiology of Microbial Diseases, Yale University, New Haven, CT, United States of America.

Joshua L Warren (JL)

Department of Biostatistics, Yale School of Public Health, New Haven, CT, United States of America.

Jon Zelner (J)

Department of Epidemiology, University of Michigan, Ann Arbor, MI, United States of America.
Center for Social Epidemiology and Population Health, University of Michigan School of Public Health, Ann Arbor, MI, United States of America.

Nicolas A Menzies (NA)

Department of Global Health and Population, Harvard T. H. Chan, School of Public Health, Boston, MA, United States of America.

Roger Calderon (R)

Socios en Salud Sucursal Peru, Lima, Peru.
Programa Acadêmico de Tuberculose, Faculdade de Medicina, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.

Carmen Contreras (C)

Socios en Salud Sucursal Peru, Lima, Peru.

Leonid Lecca (L)

Department of Global Health and Population, Harvard T. H. Chan, School of Public Health, Boston, MA, United States of America.
Socios en Salud Sucursal Peru, Lima, Peru.

Mercedes C Becerra (MC)

Department of Global Health and Population, Harvard T. H. Chan, School of Public Health, Boston, MA, United States of America.

Megan Murray (M)

Department of Global Health and Population, Harvard T. H. Chan, School of Public Health, Boston, MA, United States of America.

Ted Cohen (T)

Department of Epidemiology of Microbial Diseases, Yale University, New Haven, CT, United States of America.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH